fibrocystic change disease of breast. Diffuse cystic mastopathy
Conditions
Interventions
Intervention 1: Intervention: one tablet of Metformin 500 mg, oral, twice daily for 6 months. Intervention 2: Placebo group: vitamin E 400 mg daily, oral for six months. Intervention 3: Control group:
Treatment - Drugs
Placebo
Intervention: one tablet of Metformin 500 mg, oral, twice daily for 6 months
Placebo group: vitamin E 400 mg daily, oral for six months
Control group: don't receive any treatment.
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age between 18-40; fibrocystic breast changes Exclusion criteria: Women with malignancy; breast cancer; diabetes; using other drugs; Women with kidney, heart and lung diseases; drug intolerance
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes of the size of the cysts. Timepoint: The beginning of the study, the end of six months. Method of measurement: Sonography.;The changes of the number of the cysts. Timepoint: The beginning of the study, the end of six months. Method of measurement: Sonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| The changes of pain score. Timepoint: The beginning of the study, the end of six months. Method of measurement: Physical examination.;The change of the tenderness score. Timepoint: The beginning of the study, the end of six months. Method of measurement: Physical examination.;The changes of the breast discharge. Timepoint: The beginning of the study, the end of six months. Method of measurement: Physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAfsanehTalaei
Arak University of Medical Sciences
Outcome results
None listed